Dose-response relationship of recent antidepressants in the short-term treatment of depression

Figures & data

Table I Selective and serotonin reuptake inhibitors (SSRls) and dose-efficacy relationship in parallel-group dose comparison studies ranked in order of increased efficacy. HAMD, Hamilton Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-to-treat; LOCF, last observation carried forward; NA, not applicable; =, efficacy similar to; <, efficacy inferior to.

Table II Milnacipran and dose-efficacy relationship in parallel-group dose comparison studies ranked in order of increased efficacy. HAMD, Hamilton Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-to-treat; LOCF, last observation carried forward; NA, not applicable; =, efficacy similar to; <,efficacy inferior to.

Table III Venlafaxine and dose-efficacy relationship* in parallel-group dose comparison studies ranked in order of increased efficacy. HAMD, Hamilton Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-to-treat; LOCF, last observation carried forward; NA, not applicable; =, efficacy similar to; <, efficacy inferior to.

Table IV Selective serontonin reuptake inhibitors (SSRIs) and dose-efficacy relationship in doseaugmentation studies in nonresponders ranked in order of increased efficacy. HAMD, Hamilton Rating Scale for Depression; MADRS, Montgomery and Åsberg Depression Rating Scale; ITT, intent-totreat; LOCF, last observation carried forward; NA, not applicable; =, efficacy similar to; <, efficacy inferior to.

MontgomerySA.RasmussenJG.LybyK.ConnorP.TanghojP.Dose-response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.Int Clin Psychopharmacol.1992665S70S

 PubMed Web of Science ®Google Scholar

FeighnerJP.OveroK.Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.J Clin Psychiatry.19996082483010665628

 PubMed Web of Science ®Google Scholar

BurkeWJ.GergelI.BoseA.Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.J Clin Psychiatry.20026333133612000207

 PubMed Web of Science ®Google Scholar

WernickeJF.DunlopSR.DornseifBE.ZerbeRL.Fixed-dose fluoxetine therapy for depression.Psychopharmacol Bull.1987231641683496625

 PubMed Web of Science ®Google Scholar

WernickeJF.DunlopSR.DornseifBE.BosomworthJC.HumbertM.Lowdose fluoxetine therapy for depression.Psychopharmacol Bull.1988241831883290940

 PubMed Web of Science ®Google Scholar

WalczakDD.ApterJT.HalikasJA.et al.The oral dose-effect relationship for f luvoxamine: a fixed-dose comparison against placebo in depressed outpatients.Ann Clin Psychiatry.199681391518899132

 PubMedGoogle Scholar

DunnerDL.DunbarGC.Optimal dose regimen for paroxetine.J Clin Psychiatry.19925321S26S

 PubMed Web of Science ®Google Scholar

FabreLF.PutmanHP.A fixed-dose clinical trial of fluoxetine in outpatients with major depression.J Clin Psychiatry.1987484064083312176

 PubMed Web of Science ®Google Scholar

AnsseauM.Von FrenckellR.MertensC.et al.Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients.Psychopharmacology.1989981631682569214

 PubMed Web of Science ®Google Scholar

AnsseauM.Von FrenckellR.GerardMA.et al.Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.Eur Neuropsychopharmacol.199111131211821700

 PubMedGoogle Scholar

GuelfiJD.AnsseauM.CorrubleE.et al.A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.Int Clin Psychopharmacol.1998131211289690979

 PubMed Web of Science ®Google Scholar

MendelsJ.JohnstonR.MattesJ.RiesenbergR.Efficacy and safety of bid doses of venlafaxine in a dose-response study.Psychopharmacol Bull.1993291691748290661

 PubMed Web of Science ®Google Scholar

KhanA.Virginia UptonG.RudolphRL.EntsuahR.LeventerSM.Venlafaxine Investigator Study Group. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study.J Clin Psychopharmacol.19981819259472838

 PubMed Web of Science ®Google Scholar

DornseifBE.DunlopSR.PotvinJH.WernickeJF.Effect of dose escalation after low-dose fluoxetine therapy.Psychopharmacol Bull.19892571792672072

 PubMedGoogle Scholar

SchweizerE.RickelsK.AmsterdamJD.FoxI.PuzzuoliG.WeiseC.What constitutes an adequate antidepressant trial for fluoxetine?J Clin Psychiatry.1990518112403998

 PubMed Web of Science ®Google Scholar

BenkertO.SzegediA.WetzelH.StaabHJ.MeïsterW.PhilippM.Dose escalation vs continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.Acta PsychiatScand.199795288296

 PubMed Web of Science ®Google Scholar